Differential expression analysis in multi-omics showed that AGR2 was significantly downregulated in tumor- versus BPH-derived primary cell proteome (Wilcoxon rank-sum test, 0.49-fold, p = 0.0002, Fig. 4a) and cell-surface proteome (Wilcoxon rank-sum test, 0.17-fold, p < 0.0001, Fig. 4c), and AGR2 was also comparatively lower in tumors at mRNA level (Wilcoxon rank-sum test, 0.52-fold, p = 0.12, Supplementary Fig. 5a). This evidence concerns the gene AGR2 and benign prostatic hyperplasia.